{"entity":{"id":"genocury-biotech","kind":"company","name":"Genocury Biotech","aka":["Shenzhen Genocury Biotech Co., Ltd.","济因生物","Genocury"],"tldr":"Genocury Biotech, in Shenzhen, is testing CAR-T treatments made inside the patient's body from a single infusion, rather than in a laboratory, for lymphoma, leukaemia and myeloma. The trials are early and run by hospital investigators in China.","summary":"Shenzhen Genocury Biotech develops in vivo CAR-T therapies: an intravenous product that generates CAR-T cells inside the body. On ClinicalTrials.gov it sponsors investigator-initiated, single-centre studies of JY231 in relapsed or refractory B-cell lymphoma and leukaemia (NCT06678282, started 2023; NCT06890065, started 2025) and of JY232 in relapsed or refractory multiple myeloma (NCT07336823, registered January 2026). In April 2025 the company reported a single case from an investigator-initiated trial at Tongji Hospital: a patient with relapsed or refractory diffuse large B-cell lymphoma reached complete remission within 28 days of one dose of its in vivo CD19 CAR-T, given without lymphodepleting chemotherapy, with no cytokine release syndrome or ICANS reported. That is one patient. OrbiMed's portfolio page describes the company as developing in vivo CAR-T for oncology and autoimmune diseases. Its website also lists iPSC and reporter cell-line services.","asOf":"2026-11-04","links":[{"label":"Official website (Chinese)","url":"https://genocury.com/"},{"label":"JY231 trial NCT06678282","url":"https://clinicaltrials.gov/study/NCT06678282"},{"label":"April 2025 DLBCL case release (1stOncology)","url":"https://www.1stoncology.com/blog/?p=102826"},{"label":"OrbiMed portfolio entry","url":"https://www.orbimed.com/portfolio/"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl","all-leukemia","multiple-myeloma"],"sections":["cell-therapy","immunotherapy"],"technologies":["in-vivo-car-t","car-t"],"targets":["cd19"],"drugs":["jy231","jy232"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on a source read.","The April 2025 release does not name the product; whether JY231 is the CD19 product described is not stated, so the CD19 target is from the release and not from the registry.","The website's pipeline page loads from an API and could not be read as text; HQ is the Shenzhen address in the site footer.","None of the three Genocury trials has an OnCo trial record. ClinicalTrials.gov lists phase 'not applicable' for the JY231 studies and early phase 1 for JY232."],"hq":"Shenzhen","country":"CN","companyType":"cell-therapy","website":"https://genocury.com/","stage":"startup","investors":["orbimed"],"funding":[]},"route":"/companies/genocury-biotech/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"jy231","kind":"drug","name":"JY231","route":"/drugs/jy231/"},{"id":"jy232","kind":"drug","name":"JY232","route":"/drugs/jy232/"}],"company":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"}],"trial":[{"id":"nct06678282","kind":"trial","name":"JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia","route":"/trials/nct06678282/"},{"id":"nct06890065","kind":"trial","name":"JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia","route":"/trials/nct06890065/"},{"id":"nct07336823","kind":"trial","name":"JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07336823/"}]}}